3 citations
,
May 2021 in “British Journal of Dermatology” This study reports that COVID-19 significantly decreased skin cancer diagnoses and referrals, with reductions of up to 60% observed in the Netherlands and similar trends in the UK and Australia.
April 2026 in “International Journal of Clinical Oncology” This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.
May 2022 in “Голова и шея.” This report describes a case of a patient with metastatic renal cell carcinoma who developed a psoriasiform skin lesion while undergoing immune checkpoint inhibitor therapy.
1 citations
,
January 2025 in “Dermatologic Therapy” This study analyzed FAERS data to explore the risk and onset patterns of autoimmune skin diseases associated with immune checkpoint inhibitors, finding a strong association particularly with bullous pemphigoid and emphasizing the need for vigilant monitoring of these adverse effects.
April 2018 in “Journal of Investigative Dermatology” In this study, researchers reported that IL-17C plays a key pro-inflammatory role in human skin diseases and may be a promising therapeutic target for inflammatory skin conditions.